- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01455090
Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available Medications
Open-Label, Multiple-Dose, Dose Escalation Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Coadministration of BMS-650032, BMS-790052, and BMS-791325 When Administered for 24 or 12 Weeks in Treatment-Naïve Subjects Infected With Hepatitis C Virus Genotype 1
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Clichy Cedex, Frankreich, 92118
- Local Institution
-
Creteil Cedex, Frankreich, 9410
- Local Institution
-
Limoges, Frankreich, 87042
- Local Institution
-
Marseille Cedex 08, Frankreich, 13285
- Local Institution
-
Paris Cedex 14, Frankreich, 75679
- Local Institution
-
-
-
-
-
San Juan, Puerto Rico, 00927
- Fundacion de Investigacion de Diego
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294
- The Kirklin Clinic
-
-
California
-
Coronado, California, Vereinigte Staaten, 92118
- Southern California Research Center
-
Los Angeles, California, Vereinigte Staaten, 90073
- VA Greater Los Angeles Healthcare System
-
Los Angeles, California, Vereinigte Staaten, 90036
- Peter J Ruane Md Inc
-
San Diego, California, Vereinigte Staaten, 92105
- Research and Education, Inc.
-
San Diego, California, Vereinigte Staaten, 92123
- Medical Associates Research Group
-
San Diego, California, Vereinigte Staaten, 92114
- Precision Research Institute, LLC
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- University of Colorado Denver and Hospital
-
-
District of Columbia
-
Washington, D.C., District of Columbia, Vereinigte Staaten, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Orlando, Florida, Vereinigte Staaten, 32803
- Orlando Immunology Center
-
South Miami, Florida, Vereinigte Staaten, 33143
- Miami Research Associates
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30308
- Atlanta Gastroenterology Associates, LLC
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21202
- Mercy Medical Center, Inc.
-
Lutherville, Maryland, Vereinigte Staaten, 21093
- Johns Hopkins University
-
-
New Jersey
-
Hillsborough, New Jersey, Vereinigte Staaten, 08844
- ID Care
-
-
New Mexico
-
Santa Fe, New Mexico, Vereinigte Staaten, 87505
- Southwest CARE Center
-
-
New York
-
The Bronx, New York, Vereinigte Staaten, 10468
- James J Peters VAMC
-
-
Oklahoma
-
Tulsa, Oklahoma, Vereinigte Staaten, 74104
- Options Health Research, LLC
-
Tulsa, Oklahoma, Vereinigte Staaten, 74135
- Healthcare Research Consultants
-
-
Texas
-
Arlington, Texas, Vereinigte Staaten, 76012
- Texas Clinical Research Institute
-
Houston, Texas, Vereinigte Staaten, 77030
- Research Specialists of Texas
-
San Antonio, Texas, Vereinigte Staaten, 78215
- Alamo Medical Research
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84106
- Lifetree Clinical Research
-
-
Virginia
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- Metropolitan Research
-
Falls Church, Virginia, Vereinigte Staaten, 22042
- Inova Fairfax Hospital
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53715
- Dean Clinic
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Men and women, ages ≥18 years of age
- Subjects who are naive to HCV treatment, defined as no previous exposure to an Interferon (IFN), Ribavirin (RBV); or any HCV-specific direct acting antiviral or experimental therapy or subjects who are null responders to previous pegylated Interferon alfa (pegIFNα) plus Ribavirin (RBV) treatment
Subjects should have chronic hepatitis C (CHC) as documented by:
- Positive for anti-HCV antibody, HCV RNA, or a positive HCV genotype test at least 6 months prior to screening, and positive for HCV RNA and Anti-HCV antibody at the time of screening, or
- Positive for anti-HCV antibody and HCV RNA at the time of screening with a liver biopsy consistent with chronic HCV infection (or a liver biopsy performed prior to enrollment with evidence of CHC disease, such as the presence of fibrosis)
- HCV genotype 1a, 1b or 4 only
- HCV RNA viral load of ≥10,000 IU/mL at screening
Have one of the following:
- Documented Fibrotest score of ≤0.72 and aspartate transferase (transminase) to platelet ratio index (APRI) ≤2; OR
- Documented liver biopsy within 36 months preceding Day 1 showing absence of cirrhosis OR
- Documented Fibroscan® ultrasound (where approved) within 12 months of screening showing absence of cirrhosis
- Body mass index (BMI) of 18.0 to 35.0 kg/m2, inclusive
- Subjects with compensated Child-Pugh A cirrhosis as documented by history of cirrhosis with any prior liver biopsy or Fibroscan® ultrasound (where approved) within 12 months prior to screening
Exclusion Criteria:
- Evidence of a medical condition associated with chronic liver disease other than HCV (such as but not limited to: hemochromatosis, autoimmune hepatitis,metabolic liver disease, alcoholic liver disease, toxin exposures)
- History of variceal bleeding, hepatic encephalopathy, or ascites requiring management with diuretics or paracentesis
- Current or known history of cancer (except in situ carcinoma of the cervix or adequately treated basal or squamous cell carcinoma of the skin) within 5 years prior to enrollment
- Documented or suspected hepatocellular carcinoma (HCC)
- Positive for hepatitis B surface antigen (HBsAg)
- Positive for Human Immunodeficiency Virus-1 (HIV-1) and/or Human Immunodeficiency Virus-2 (HIV-2) antibodies
- Alanine transferase (transminase) (ALT) >5x upper limit of normal (ULN)
- Total Bilirubin ≥2 mg/dL
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Group 1:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)
BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks BMS-790052 60 mg tablet by mouth once daily for 24 Weeks BMS 791325 75 mg table by mouth twice daily for 24 Weeks |
Andere Namen:
Andere Namen:
|
Experimental: Group 2:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(75mg)
BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 60 mg tablet by mouth once daily for 12 Weeks BMS 791325 75 mg table by mouth twice daily for 12 Weeks |
Andere Namen:
Andere Namen:
|
Experimental: Group 3:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)
* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2 BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks BMS-790052 60 mg tablet by mouth once daily for 24 Weeks BMS 791325 150 mg table by mouth twice daily for 24 Weeks |
Andere Namen:
Andere Namen:
|
Experimental: Group 4:BMS-650032(200 mg)+BMS-790052(60 mg)+BMS-791325(150mg)
* Contingent upon review of safety data from all available treated subjects from Groups 1 and 2 BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 60 mg tablet by mouth once daily for 12 Weeks BMS 791325 150 mg table by mouth twice daily for 12 Weeks |
Andere Namen:
Andere Namen:
|
Experimental: Group 5:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)
* Genotype 1 treatment-naive subjects BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks BMS 791325 75 mg table by mouth twice daily for 12 Weeks |
Andere Namen:
Andere Namen:
|
Experimental: Group 6:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)
* Genotype 1 treatment-naive subjects BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks BMS 791325 150 mg table by mouth twice daily for 12 Weeks |
Andere Namen:
Andere Namen:
|
Experimental: Group 7:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)
* Genotype 4 treatment-naive subjects BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks BMS 791325 75 mg table by mouth twice daily for 12 Weeks |
Andere Namen:
Andere Namen:
|
Experimental: Group 8:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)
* Genotype 4 treatment-naive subjects BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks BMS 791325 150 mg table by mouth twice daily for 12 Weeks |
Andere Namen:
Andere Namen:
|
Experimental: Group 9:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)
* Genotype 1 treatment-null/non-responder subjects BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks BMS 791325 75 mg table by mouth twice daily for 12 Weeks |
Andere Namen:
Andere Namen:
|
Experimental: Group10:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)
* Genotype 1 treatment-null/non-responder subjects BMS-650032 200 mg tablet by mouth twice daily for 12 Weeks BMS-790052 30 mg tablet by mouth twice daily for 12 Weeks BMS 791325 150 mg table by mouth twice daily for 12 Weeks |
Andere Namen:
Andere Namen:
|
Experimental: Group11:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(75mg)
* Genotype 1 treatment-null/non-responder subjects BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks BMS 791325 75 mg table by mouth twice daily for 24 Weeks |
Andere Namen:
Andere Namen:
|
Experimental: Group12:BMS-650032(200 mg)+BMS-790052(30 mg)+BMS-791325(150mg)
* Genotype 1 treatment-null/non-responder subjects BMS-650032 200 mg tablet by mouth twice daily for 24 Weeks BMS-790052 30 mg tablet by mouth twice daily for 24 Weeks BMS 791325 150 mg table by mouth twice daily for 24 Weeks |
Andere Namen:
Andere Namen:
|
Experimental: Grp13:BMS-650032(200mg)+BMS-790052(30mg)+BMS-791325(75mg)+RBV
* Genotype 1 treatment-naive subjects BMS-650032 200 mg tablets orally twice daily 12 weeks BMS-790052 30 mg tablets orally twice daily 12 weeks BMS-791325 75 mg tablets orally twice daily 12 weeks Ribavirin (RBV) tablets orally weight based dosing daily 12 weeks [if subject is < 75 kg: 1000 mg per day orally (2 x 200 mg tablets in AM and 3 x 200 mg tablets in PM), or if ≥ 75 kg: 1200 mg per day orally (3 x 200 mg tablets in AM and 3 x 200 mg tablets in PM] |
Andere Namen:
Andere Namen:
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Sustained virologic response (SVR) at 12 weeks post-treatment (SVR12)
Zeitfenster: 12 weeks post-treatment
|
12 weeks post-treatment
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Proportion of subjects with HCV ribonucleic acid (RNA) < limit of quantification (LOQ) (detectable and undetectable)
Zeitfenster: Weeks 1, 2, 4, 6, 8, 10, 12,14, 16, 18, 20, 22 and 24 weeks of therapy; at end of treatment (EOT) (following 12 or 24 weeks of treatment, by Group); and Weeks 4, 12, 24, 36, and 48 weeks post-treatment
|
Weeks 1, 2, 4, 6, 8, 10, 12,14, 16, 18, 20, 22 and 24 weeks of therapy; at end of treatment (EOT) (following 12 or 24 weeks of treatment, by Group); and Weeks 4, 12, 24, 36, and 48 weeks post-treatment
|
|
Proportion of subjects with HCV ribonucleic acid (RNA) undetectable
Zeitfenster: Weeks 1, 2, 4, 6, 8, 10, 12,14, 16, 18, 20, 22 and 24 weeks of therapy; at end of treatment (EOT) (following 12 or 24 weeks of treatment, by Group); and Weeks 4, 12, 24, 36, and 48 weeks post-treatment
|
Weeks 1, 2, 4, 6, 8, 10, 12,14, 16, 18, 20, 22 and 24 weeks of therapy; at end of treatment (EOT) (following 12 or 24 weeks of treatment, by Group); and Weeks 4, 12, 24, 36, and 48 weeks post-treatment
|
|
Proportion of subjects who experience viral breakthrough
Zeitfenster: Formal analysis at SVR12, Week 48 of follow up period (or upon occurrence)
|
viral breakthrough defined as:
|
Formal analysis at SVR12, Week 48 of follow up period (or upon occurrence)
|
Proportion of subjects who experience viral relapse defined as confirmed quantifiable HCV RNA ≥ 25 IU/mL (>LOQ) in a subject with HCV RNA < LOQ or undetectable at End of treatment (EOT)
Zeitfenster: End of treatment (Maximum up to 24 Weeks)
|
End of treatment (Maximum up to 24 Weeks)
|
|
Maximum observed plasma concentration (Cmax) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712
Zeitfenster: Day 1 and Day 14
|
Day 1 and Day 14
|
|
Observed plasma concentration at 12 hours (C12) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712
Zeitfenster: Day 1 and Day 14
|
Day 1 and Day 14
|
|
Observed plasma concentration at 24 hours (C24) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712
Zeitfenster: Day 1 and Day 14
|
Day 1 and Day 14
|
|
Trough observed plasma concentration (Ctrough) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712
Zeitfenster: Day 1 and Day 14
|
Day 1 and Day 14
|
|
Time of maximum observed plasma concentration (Tmax) of BMS-650032, BMS-790052, BMS 791325, and BMS-794712
Zeitfenster: Day 1 and Day 14
|
Day 1 and Day 14
|
|
Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-650032, BMS-790052, BMS 791325, and BMS-794712
Zeitfenster: Day 1 and Day 14
|
Day 1 and Day 14
|
|
HCV genomic substitutions associated with exposure of BMS-650032, BMS-790052, and BMS-791325
Zeitfenster: At the time of viral breakthrough or relapse
|
At the time of viral breakthrough or relapse
|
|
Frequency of deaths, serious adverse events (SAEs), discontinuations due to adverse events (AEs), severity Grade 3/4 AEs, and severity Grade 3/4 laboratory abnormalities
Zeitfenster: Formal analysis at week 48 of follow up period (or upon occurrence)
|
Formal analysis at week 48 of follow up period (or upon occurrence)
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Desta T, Hawkins T, Levin JM, Hinestrosa F, Rustgi V, Schwartz H, Younossi Z, Webster L, Gitlin N, Eley T, Huang SP, McPhee F, Grasela DM, Gardiner DF. Daclatasvir + asunaprevir + beclabuvir +/- ribavirin for chronic HCV genotype 1-infected treatment-naive patients. Liver Int. 2016 Feb;36(2):189-97. doi: 10.1111/liv.12964. Epub 2015 Dec 6.
- Everson GT, Sims KD, Rodriguez-Torres M, Hezode C, Lawitz E, Bourliere M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H, Marcellin P, Pol S, Thuluvath PJ, Eley T, Wang X, Huang SP, McPhee F, Wind-Rotolo M, Chung E, Pasquinelli C, Grasela DM, Gardiner DF. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014 Feb;146(2):420-9. doi: 10.1053/j.gastro.2013.10.057. Epub 2013 Oct 30.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Leberkrankheiten
- Flaviviridae-Infektionen
- Hepatitis, viral, menschlich
- Enterovirus-Infektionen
- Picornaviridae-Infektionen
- Hepatitis, chronisch
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, chronisch
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Enzym-Inhibitoren
- Antimetaboliten
- Protease-Inhibitoren
- Ribavirin
- Asunaprevir
Andere Studien-ID-Nummern
- AI443-014
- 2011-002788-11 (EudraCT-Nummer)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Chronische Hepatitis C
-
Tripep ABInovio PharmaceuticalsUnbekanntChronische Hepatitis-C-VirusinfektionSchweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsZurückgezogenChronische Hepatitis-C-VirusinfektionIsrael
-
Hadassah Medical OrganizationUnbekanntChronische Hepatitis-C-VirusinfektionIsrael
-
Trek Therapeutics, PBCAbgeschlossenChronische Hepatitis C | Hepatitis-C-Genotyp 1 | Hepatitis C (HCV) | Hepatitis-C-VirusinfektionVereinigte Staaten, Neuseeland
-
Trek Therapeutics, PBCAbgeschlossenChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis-C-Genotyp 4 | Hepatitis-C-VirusinfektionVereinigte Staaten
-
AbbVieAbgeschlossenChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis-C-Genotyp 1a
-
AbbVie (prior sponsor, Abbott)AbgeschlossenChronische Hepatitis C | Hepatitis-C-Genotyp 1 | Hepatitis C (HCV)Vereinigte Staaten, Australien, Kanada, Frankreich, Deutschland, Neuseeland, Puerto Rico, Spanien, Vereinigtes Königreich
-
AbbVieAbgeschlossenHepatitis-C-Virus | Chronisches Hepatitis-C-Virus
-
Beni-Suef UniversityAbgeschlossenChronische Hepatitis-C-VirusinfektionÄgypten
-
Humanity and Health Research CentreBeijing 302 HospitalAbgeschlossenChronische Hepatitis-C-InfektionChina
Klinische Studien zur BMS-791325
-
Bristol-Myers SquibbAbgeschlossen
-
Bristol-Myers SquibbZurückgezogenHepatitis-C-VirusVereinigte Staaten
-
Bristol-Myers SquibbAbgeschlossenHepatitis-C-VirusKorea, Republik von, Taiwan, Russische Föderation
-
Timothy Morgan, MDBristol-Myers Squibb; National Cancer Institute (NCI); VA Long Beach Healthcare...Abgeschlossen
-
Bristol-Myers SquibbAbgeschlossenHepatitis CVereinigte Staaten, Australien, Kanada, Frankreich, Puerto Rico
-
Bristol-Myers SquibbAbgeschlossenHepatitis CVereinigte Staaten
-
National Institutes of Health Clinical Center (CC)Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases...Abgeschlossen
-
Bristol-Myers SquibbAbgeschlossenHepatitis CVereinigte Staaten, Australien, Kanada, Frankreich
-
Bristol-Myers SquibbAbgeschlossen